Inventor · disambiguated record
Thomas Weimer
Also filed as: WEIMER THOMAS
27 granted patents·27 pending applications·331 citations·filing 1998–2020
96Inventor score
Files withCSL BEHRING GMBH13CSL Behring Lengnau AG9AVENTIS BEHRING GMBH7WEIMER THOMAS6SCHULTE STEFAN4
Top patents by PatentIndex Score
54 records- 0197US7939632B2Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2007·Granted May 10, 2011·40 cites·31 claims
- 0291US8283319B2Therapeutic application of Kazal-type serine protease inhibitorsSCHULTE STEFAN·Filed 2008·Granted Oct 9, 2012·33 cites·17 claims
- 0391US6573081B2Method for growing circovirusesAVENTIS BEHRING GMBH·Filed 2001·Granted Jun 3, 2003·39 cites·3 claims
- 0489US8754194B2Modified coagulation factors with prolonged in vivo half-lifeSCHULTE STEFAN·Filed 2007·Granted Jun 17, 2014·12 cites·15 claims
- 0588US9878017B2Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating theretoCSL LTD·Filed 2014·Granted Jan 30, 2018·4 cites·20 claims
- 0688US8575104B2Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2009·Granted Nov 5, 2013·18 cites·27 claims
- 0787US6248526B1Labeled primer for use in and detection of target nucleic acidsAVENTIS BEHRING GMBH·Filed 1998·Granted Jun 19, 2001·128 cites·22 claims
- 0884US10688157B2Truncated von Willebrand factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2016·Granted Jun 23, 2020·2 cites·23 claims
- 0984US8765915B2Modified coagulation factor VIIa with extended half-lifeWEIMER THOMAS·Filed 2007·Granted Jul 1, 2014·8 cites·13 claims
- 1083US9458223B2Von willebrand factor variants having improved factor VIII binding affinityCSL BEHRING GMBH·Filed 2013·Granted Oct 4, 2016·8 cites·20 claims
- 1183US6831167B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesAVENTIS BEHRING GMBH·Filed 2001·Granted Dec 14, 2004·9 cites·6 claims
- 1282US10905747B2Methods for preparing modified von Willebrand factorCSL Behring Lengnau AG·Filed 2020·Granted Feb 2, 2021·1 cites·14 claims
- 1382US9347051B2Coagulation factor X polypeptides with modified activation propertiesSCHULTE STEFAN·Filed 2007·Granted May 24, 2016·6 cites·4 claims
- 1479US7153679B2Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosisAVENTIS BEHRING GMBH·Filed 2003·Granted Dec 26, 2006·9 cites·20 claims
- 1568US11564976B2Methods for preparing modified von Willebrand FactorCSL Behring Lengnau AG·Filed 2020·Granted Jan 31, 2023·0 cites·15 claims
- 1668US9290561B2Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2013·Granted Mar 22, 2016·1 cites·31 claims
- 1767US2020095567A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 1867US2018119128A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2017·Application pending·0 cites
- 1965US7863009B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2008·Granted Jan 4, 2011·0 cites·8 claims
- 2063US7442514B2Mutants of the factor VII-activating protease and detection methods using specific antibodiesCSL BEHRING GMBH·Filed 2004·Granted Oct 28, 2008·0 cites·19 claims
- 2162US2010143973A1Interleukin-11 Fusion ProteinsKROEZ MONIKA·Filed 2009·Application pending·0 cites
- 2260US2009227775A1HIV Inhibiting ProteinsNOVOZYMES BIOPHARMA UK LTD·Filed 2009·Application pending·0 cites
- 2360US2008274969A1Albumin-Fused Kunitz Domain PeptidesNOVOZYMES DELTA LTD·Filed 2008·Application pending·0 cites
- 2459US2011189182A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2011·Application pending·0 cites
- 2559US2016010074A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2015·Application pending·0 cites
- 2658US2008293638A1Albumin-fused ciliary neurotrophic factorNOVOZYMES BIOPHARMA UK LTD·Filed 2008·Application pending·0 cites
- 2757US2008292581A1Interleukin-11 Fusion ProteinsDELTA BIOTECHNOLOGY LTD·Filed 2004·Application pending·0 cites
- 2857US2014248686A1Therapeutic polypeptides with increased in vivo recoveryCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 2956US10772936B2Methods for preparing modified von Willebrand factorCSL Behring Lengnau AG·Filed 2016·Granted Sep 15, 2020·0 cites·13 claims
- 3056US7803569B2Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutationsCSL BEHRING GMBH·Filed 2006·Granted Sep 28, 2010·0 cites·20 claims
- 3156US2014356346A1MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFECSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 3256US2003186307A1Method for growing or for removing circoviruses from biological materialAVENTIS BEHRING GMBH·Filed 2003·Application pending·0 cites
- 3356US2010222554A1Method of Increasing the In Vivo Recovery of Therapeutic PolypeptidesWEIMER THOMAS·Filed 2007·Application pending·0 cites
- 3454US2013337532A1Therapeutic polypeptides with increased in vivo recoveryWEIMER THOMAS·Filed 2013·Application pending·0 cites
- 3554US2018092966A1Covalent complex of von willebrand factor and factor viii, compositions, and uses relating theretoCSL LTD·Filed 2017·Application pending·0 cites
- 3653US2014273096A1Modified coagulation factors with prolonged in vivo half-lifeCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 3752US6183999B1Procedure for the detection of high virus concentrations in blood plasma and/or blood serum by means of the polymerase chain reactionAVENTIS BEHRING GMBH·Filed 1998·Granted Feb 6, 2001·13 cites·6 claims
- 3852US2002164596A1Proccess for finding oligonuclestide sequences for nucleic acid amplification methodsAVENTIS BEHRING GMBH·Filed 2001·Application pending·0 cites
- 3951US2011092413A1Albumin-Fused Kunitz Domain PeptidesNOVOZYMES BIOPHARMA DK AS·Filed 2010·Application pending·0 cites
- 4049US2006241027A1Hiv inhibiting proteinsHAUSER HANS-PETER·Filed 2003·Application pending·0 cites
- 4149US2012258072A1Interleukin-11 Fusion ProteinsKROEZ MONIKA·Filed 2011·Application pending·0 cites
- 4249US2017080061A1MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFECSL BEHRING GMBH·Filed 2016·Application pending·0 cites
- 4349US2006178301A1Albumin-fused ciliary neurotrophic factorJURS MATHIAS·Filed 2005·Application pending·0 cites
- 4447US2009042787A1Proteolytically cleavable fusion proteins with high molar specific activityMETZNER HUBERT·Filed 2007·Application pending·0 cites
- 4545US9249404B2Coagulation factor X polypeptides with modified activation propertiesSCHULTE STEFAN·Filed 2006·Granted Feb 2, 2016·0 cites·9 claims
- 4645US2005222023A1Albumin-fused kunitz domain peptidesHAUSER HANS-PETER·Filed 2003·Application pending·0 cites
- 4744US11141466B2Modulation of FVIII immunogenicity by truncated VWFCSL Behring Lengnau AG·Filed 2018·Granted Oct 12, 2021·0 cites·20 claims
- 4843US11890327B2Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorderCSL Behring Lengnau AG·Filed 2017·Granted Feb 6, 2024·0 cites·23 claims
- 4943US11814421B2Truncated von Willebrand Factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2017·Granted Nov 14, 2023·0 cites·24 claims
- 5043US2022348637A1Polypeptides for inducing tolerance to factor viiiCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Weimer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →